Wolf Chanoff's questions to Evotec (EVO) leadership • Q2 2023
Question
Asked about budget tightening among large pharma clients and requested the size of the API manufacturing business, along with the risk of losing market share due to the cyberattack's after-effects.
Answer
While there is some industry-wide budget tightening, Evotec's strategic, long-term partnerships with large pharma are less affected than commoditized services. The API business is part of a larger development segment (~€150-170M), with the affected GMP portion being about a third of that. The platforms are fully back online, and the company is rebuilding business development momentum.